Johnson & Johnson Innovation – JJDC

Activity in this selectionJun 30, 2026 · Jun 1, 2026

By stage

Seed1

Series B1

Series C+1

Biotech2

Healthtech1

United States2

United Kingdom1

3 in this selection

Jun 23

Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases

$47MSeed+

Role not disclosed

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jun 4

Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases

$85MSeries C

Role not disclosed